Back to table of contents Previous article Next article Annual MeetingFull AccessKetamine Comparable to ECT for Many Patients With Refractory DepressionNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:24 Jul 2023https://doi.org/10.1176/appi.pn.2023.08.7.47AbstractFollowing a presentation of new clinical trial data at the Annual Meeting, some questioned why...
We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using...
PsyArXivJuly 21, 2023Rediet Emebet Getnet Alemu, Joan Kamere, Rosine Baseke et al.
preprint
Background: Depressive and anxiety symptoms significantly impact the well-being of African youth. This problem is compounded by limited access to appropriate mental health care services and societal stigma. In addressing this issue in Kenya, we employed the network approach to psychopathology to identity the most significant symptoms of depression and anxiety. These network analyses revealed...
Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its psychotherapies often involve delayed treatment-response times, while its pharmacotherapies can cause unwanted side effects. In recent years, there has been a resurgence in psychedelic research with a specific interest in the potential of psilocybin for treating MDD. Therefore, this systematic review was...
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
Women with gynecologic cancers face various physical and psychological challenges throughout their treatment journey. Late stages associated with poor prognosis, along with chronic side effects of treatment, often leave women with existential uncertainty stemming from unpredictable disease trajectory and continuous fear of death. Recently, a patient in her late 30s (JN) with endstage ovarian...
Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects necessitating effective, fast-acting, and better tolerated alternatives. The purpose of this review is to describe the safety and efficacy of...
Between 40 and 50% of patients with Parkinson's disease (PD) experience anxiety and depression, associated with impaired physical function, high care dependency and mortality. Recently, the United States National Institutes of Health has urged the implementation of mindfulness practices in chronic illness care. Most research to date has examined the effects on chronically ill patients of...
Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) methods incorporate music as a key element. Music is an effective emotional/hedonic stimulus that could also be useful in assessing changes in emotional responsiveness following PT. Brain responses to music were assessed before and after PT using...
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed. Aims To assess the acute efficacy and safety of a 4-week course of subcutaneous racemic ketamine in participants with TRD. Trial registration: ACTRN12616001096448 at www.anzctr.org.au. Method This phase 3,...